A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Solid Tumors|Breast Cancer|Cowden Syndrome
Interventions: DRUG: BGT226
Sponsor: Novartis Pharmaceuticals